In addition to NSE and S100B, several emerging neurobiomarkers—such as neurofilament light chain (NfL), Tau, and glial fibrillary acidic protein (GFAP)—have shown promise for outcome prediction after cardiac arrest [31–33]. This evidence concerns the gene ENO2 and cardiac arrest.